209 related articles for article (PubMed ID: 31308416)
1. Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study.
Manzoor S; Ganie MA; Amin S; Shah ZA; Bhat IA; Yousuf SD; Jeelani H; Kawa IA; Fatima Q; Rashid F
Sci Rep; 2019 Jul; 9(1):10182. PubMed ID: 31308416
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women.
Yousuf SD; Ganie MA; Urwat U; Andrabi SM; Zargar MA; Dar MA; Manzoor-Ul-Rehman M; Mudassar S; Rashid F
BMC Womens Health; 2023 Feb; 23(1):68. PubMed ID: 36793022
[TBL] [Abstract][Full Text] [Related]
3. Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study.
Yousuf SD; Ganie MA; Jeelani S; Mudassar S; Shah ZA; Zargar MA; Amin S; Wani IA; Rashid F
Indian J Med Res; 2018 Dec; 148(Suppl):S151-S155. PubMed ID: 30964093
[TBL] [Abstract][Full Text] [Related]
4. Does the Oral Contraceptive Pill Increase Plasma Intercellular Adhesion Molecule-1, Monocyte Chemoattractant Protein-1, and Tumor Necrosis Factor-α Levels in Women with Polycystic Ovary Syndrome: A Pilot Study.
Yousuf SD; Rashid F; Mattoo T; Shekhar C; Mudassar S; Zargar MA; Ganie MA
J Pediatr Adolesc Gynecol; 2017 Feb; 30(1):58-62. PubMed ID: 27381237
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
6. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.
Hutchison SK; Harrison C; Stepto N; Meyer C; Teede HJ
Diabetes Care; 2008 Jul; 31(7):1427-32. PubMed ID: 18390799
[TBL] [Abstract][Full Text] [Related]
7. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
Sahu A; Tripathy P; Mohanty J; Nagy A
J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
[TBL] [Abstract][Full Text] [Related]
8. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
Elter K; Imir G; Durmusoglu F
Hum Reprod; 2002 Jul; 17(7):1729-37. PubMed ID: 12093831
[TBL] [Abstract][Full Text] [Related]
9. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Kaya MG; Calapkorur B; Karaca Z; Yildirim S; Celik A; Akpek M; Unluhizarci K; Kelestimur F
Clin Endocrinol (Oxf); 2012 Dec; 77(6):885-92. PubMed ID: 22563947
[TBL] [Abstract][Full Text] [Related]
10. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
Kilic S; Yilmaz N; Zulfikaroglu E; Erdogan G; Aydin M; Batioglu S
Gynecol Endocrinol; 2011 Sep; 27(9):622-9. PubMed ID: 21105835
[TBL] [Abstract][Full Text] [Related]
12. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
13. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
[TBL] [Abstract][Full Text] [Related]
14. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
[TBL] [Abstract][Full Text] [Related]
15. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
[TBL] [Abstract][Full Text] [Related]
16. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
17. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
18. Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.
Glintborg D; Mumm H; Altinok ML; Richelsen B; Bruun JM; Andersen M
J Endocrinol Invest; 2014 Aug; 37(8):757-764. PubMed ID: 24906976
[TBL] [Abstract][Full Text] [Related]
19. Interventions for hirsutism (excluding laser and photoepilation therapy alone).
van Zuuren EJ; Fedorowicz Z; Carter B; Pandis N
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010334. PubMed ID: 25918921
[TBL] [Abstract][Full Text] [Related]
20. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
Harmanci A; Cinar N; Bayraktar M; Yildiz BO
Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
